A retrospective study of glycemic control and safety of insulin degludec/insulin aspart (IDegAsp) co-formulation in Japanese patients with type 2 diabetes (T2D)
Latest Information Update: 12 Feb 2021
Price :
$35 *
At a glance
- Drugs Insulin degludec/insulin aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms JAGUAR
- 12 Feb 2021 New trial record
- 09 Feb 2021 Results published in the Advances in Therapy